Concordance of programmed death-ligand 1 expression assessments determined via two immunohistochemical tests and the polymerase chain reaction method

Table 2 Frequency of programmed death-ligand 1 expression depending on marker determination methods and the clinical and pathological characteristics of breast cancer patients

BC characteristics	Programmed cell death protein 1 Ligand 1 score				SP142 score				Polymerase chain reaction test				P value or χ² test
	< 10%		≥ 10%		< 1%		≥ 1%		Negative		Positive
	n	%	n	%	n	%	n	%	n	%	n	%
T stage
Тin situ	2	50.0	2	50.0	4	100	0	0	4	100	0	0	0.0211, 0.262, 0.0053
Т1в	4	36.4	7	63.6	6	54.6	5	45.4	4	36.4	7	63.6
Т1с	59	66.3	30	33.7	68	76.4	21	23.6	76	85.4	13	14.6
Т2	36	81.8	8	18.2	34	77.3	10	22.7	29	65.9	15	34.1
N stage
N0	58	71.6	23	28.4	60	74.1	21	25.9	61	75.3	20	24.7	0.701, 0.432, 0.733
N1	31	66.0	16	34.0	36	76.6	11	23.4	36	76.6	11	23.4
N2-3	12	60.0	8	40.0	16	80.0	4	20.0	16	80.0	4	20.0
Tumor grade
G1	10	62.5	6	37.5	14	87.5	2	12.5	12	75.0	4	25.0	0.251, 0.000152, 0.823
G2	64	73.6	23	26.4	74	85.1	13	14.9	68	78.2	19	21.8
G3	27	60.0	18	40.0	24	53.3	21	46.7	33	73.3	12	26.7
Lymphovascular invasion
Absent	60	71.4	24	28.6	66	78.6	18	21.4	64	76.2	20	23.8	0.341, 0.352, 0.963
Present	41	64.1	23	35.9	46	71.9	18	28.1	49	76.6	15	23.4
Perineural invasion
Absent	79	68.7	36	31.3	84	73.0	31	27.0	84	73.0	31	27.0	0.821, 0.162, 0.083
Present	22	66.7	11	33.3	28	84.9	5	15.1	29	87.9	4	12.1
Intraductal component
Absent	73	68.2	34	31.8	78	72.9	29	27.1	85	79.4	22	20.6	0.991, 0.202, 0.153
Present	28	68.3	13	31.7	34	82.9	7	17.1	28	68.3	13	31.7
Estrogen receptor status
Negative	5	31.3	11	68.7	0	0	16	100	10	62.5	6	37.5	0.00081, 0.00002, 0.173
Positive	96	72.7	36	27.3	112	84.9	20	15.1	103	78.0	29	22.0
Progesterone receptor status
Negative	25	61.0	16	39.0	16	39.0	25	61.0	27	65.8	14	34.2	0.241, 0.00002, 0.0633
Positive	76	71.0	31	29.0	96	89.7	11	10.3	86	80.4	21	19.6
HER2 status
Negative	99	77.3	29	22.7	112	87.5	16	12.5	103	80.5	25	19.5	0.00001, 0.00002, 0.0033
Positive	2	10.0	18	90.0	0	0	20	100	10	50.0	10	50.0
BC subtypes
Luminal A	42	75.0	14	25.0	50	89.3	6	10.7	50	89.3	6	10.7	0.00001, 0.00002, 0.00053
Luminal B HER2-	54	81.8	12	18.2	62	93.9	4	6.1	50	75.8	16	24.2
Luminal B HER2+	0	0	10	100	0	0	10	100	3	30.0	7	70.0
Nonluminal HER2+	2	20.0	8	80.0	0	0	10	100	7	70.0	3	30.0
Triple negative BC	3	50.0	3	50.0	0	0	6	100	3	50.0	3	50.0

¹Programmed cell death protein 1 Ligand 1 score.

²SP142 score.

³Polymerase chain reaction test.

BC: Breast cancer; HER2: Human epidermal growth factor receptor-2.